Prurigo nodularis : Epidemiology and clinical features - 09/11/20

Doi : 10.1016/j.jaad.2020.04.183

Amy H. Huang, MPH ^a,^b, Kyle A. Williams, BS ^a, Shawn G. Kwatra, MD ^a,^b,^⁎
^a Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
^b Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland

^∗Correspondence to: Shawn G. Kwatra, MD, Cancer Research Building II, Johns Hopkins University School of Medicine, Ste 206, 1550 Orleans St, Baltimore, MD 21231.Cancer Research Building IIJohns Hopkins University School of MedicineSte 2061550 Orleans StBaltimoreMD21231

Abstract

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules that favor the extensor surfaces of the extremities and the trunk. In addition to its significant impact on quality of life, many patients with PN are recalcitrant to therapy because there are currently no therapies approved by the US Food and Drug Administration. In the first article of this 2-part continuing medical education series, we describe the broader epidemiology, patient demographics, physical examination findings, and symptoms to aid in the timely recognition and diagnosis of PN. Furthermore, we quantify the burden of comorbidities in PN by discussing the broad spectrum of systemic diseases and mental health conditions that have been associated with this condition. The second article of this 2-part series focuses on the pathogenesis of PN and provides detailed algorithms for comprehensive work-up and management.

Le texte complet de cet article est disponible en PDF.

Key words : clinical features, comorbidities, epidemiology, itch, physical examination, prurigo nodularis, pruritus, symptoms

Plan

Clinical features of prurigo nodularis

Key points

Patient demographics and epidemiology

Other demographic variables

Associated comorbid conditions

Key points

Mental health

Infectious

Autoimmune and autoinflammatory

Dermatologic and allergic

Malignancies

Endocrine

Other systemic diseases

	Funding sources: Dr Kwatra received grant funding from the Skin of Color Society and is a recipient of the Dermatology Foundation Medical Dermatology Career Development Award.
	Date of release: December 2020.
	Expiration date: December 2023.
	Conflicts of interest: Dr Kwatra is an advisory board member for Pfizer Inc, Regeneron Pharmaceuticals, and Menlo Therapeutics and has received grant funding from Pfizer Inc and Kiniksa Pharmaceuticals. The other authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).